TDP-43-regulated cryptic RNAs accumulate in Alzheimer's disease brains.
Alzheimer’s disease
Cryptic RNA
LATE
STMN2
TDP-43
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
received:
22
05
2023
accepted:
04
08
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Inclusions of TAR DNA-binding protein 43 kDa (TDP-43) has been designated limbic-predominant, age-related TDP-43 encephalopathy (LATE), with or without co-occurrence of Alzheimer's disease (AD). Approximately, 30-70% AD cases present TDP-43 proteinopathy (AD-TDP), and a greater disease severity compared to AD patients without TDP-43 pathology. However, it remains unclear to what extent TDP-43 dysfunction is involved in AD pathogenesis. To investigate whether TDP-43 dysfunction is a prominent feature in AD-TDP cases, we evaluated whether non-conserved cryptic exons, which serve as a marker of TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), accumulate in AD-TDP brains. We assessed a cohort of 192 post-mortem brains from three different brain regions: amygdala, hippocampus, and frontal cortex. Following RNA and protein extraction, qRT-PCR and immunoassays were performed to quantify the accumulation of cryptic RNA targets and phosphorylated TDP-43 pathology, respectively. We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases. The topographic distribution of cryptic RNA accumulation mimicked that of phosphorylated TDP-43, regardless of TDP-43 subtype classification. Further, cryptic RNAs efficiently discriminated AD-TDP cases from controls. Overall, our results indicate that cryptic RNAs may represent an intriguing new therapeutic and diagnostic target in AD, and that methods aimed at detecting and measuring these species in patient biofluids could be used as a reliable tool to assess TDP-43 pathology in AD. Our work also raises the possibility that TDP-43 dysfunction and related changes in cryptic splicing could represent a common molecular mechanism shared between AD-TDP and FTLD-TDP.
Sections du résumé
BACKGROUND
Inclusions of TAR DNA-binding protein 43 kDa (TDP-43) has been designated limbic-predominant, age-related TDP-43 encephalopathy (LATE), with or without co-occurrence of Alzheimer's disease (AD). Approximately, 30-70% AD cases present TDP-43 proteinopathy (AD-TDP), and a greater disease severity compared to AD patients without TDP-43 pathology. However, it remains unclear to what extent TDP-43 dysfunction is involved in AD pathogenesis.
METHODS
To investigate whether TDP-43 dysfunction is a prominent feature in AD-TDP cases, we evaluated whether non-conserved cryptic exons, which serve as a marker of TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), accumulate in AD-TDP brains. We assessed a cohort of 192 post-mortem brains from three different brain regions: amygdala, hippocampus, and frontal cortex. Following RNA and protein extraction, qRT-PCR and immunoassays were performed to quantify the accumulation of cryptic RNA targets and phosphorylated TDP-43 pathology, respectively.
RESULTS
We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases. The topographic distribution of cryptic RNA accumulation mimicked that of phosphorylated TDP-43, regardless of TDP-43 subtype classification. Further, cryptic RNAs efficiently discriminated AD-TDP cases from controls.
CONCLUSIONS
Overall, our results indicate that cryptic RNAs may represent an intriguing new therapeutic and diagnostic target in AD, and that methods aimed at detecting and measuring these species in patient biofluids could be used as a reliable tool to assess TDP-43 pathology in AD. Our work also raises the possibility that TDP-43 dysfunction and related changes in cryptic splicing could represent a common molecular mechanism shared between AD-TDP and FTLD-TDP.
Identifiants
pubmed: 37605276
doi: 10.1186/s13024-023-00646-z
pii: 10.1186/s13024-023-00646-z
pmc: PMC10441763
doi:
Substances chimiques
DNA-Binding Proteins
0
TARDBP protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Subventions
Organisme : NINDS NIH HHS
ID : RF1 NS120992
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063911
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NINDS NIH HHS
ID : P01 NS084974
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG037491
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS123743
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS097273
Pays : United States
Informations de copyright
© 2023. Editorial Group and BioMed Central Ltd., part of Springer Nature.
Références
Brain Res. 2007 Dec 12;1184:284-94
pubmed: 17963732
J Neurosci. 2011 Oct 19;31(42):15026-34
pubmed: 22016536
Nat Neurosci. 2019 Feb;22(2):180-190
pubmed: 30643298
J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64
pubmed: 18520774
Neurosci Lett. 2009 Sep 11;461(1):25-9
pubmed: 19463897
Ann Neurol. 2007 May;61(5):435-45
pubmed: 17469117
Acta Neuropathol Commun. 2020 Apr 29;8(1):61
pubmed: 32349792
J Clin Invest. 2020 Nov 2;130(11):6080-6092
pubmed: 32790644
J Neuropathol Exp Neurol. 2008 Apr;67(4):271-9
pubmed: 18379440
Neurology. 2020 Jul 7;95(1):e23-e34
pubmed: 32518145
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurobiol Aging. 1995 Nov-Dec;16(6):883-94
pubmed: 8622778
Ann Neurol. 2013 Jul;74(1):20-38
pubmed: 23686809
Acta Neuropathol. 2016 Apr;131(4):571-85
pubmed: 26810071
Neuron. 2022 May 18;110(10):1671-1688.e6
pubmed: 35294901
Acta Neuropathol. 2019 Feb;137(2):227-238
pubmed: 30604226
Lancet Neurol. 2011 Sep;10(9):785-96
pubmed: 21802369
BMC Med Genomics. 2017 May 26;10(1):38
pubmed: 28549443
Nat Commun. 2018 Nov 14;9(1):4780
pubmed: 30429473
Neuron. 2013 Aug 7;79(3):416-38
pubmed: 23931993
Nature. 2022 Mar;603(7899):124-130
pubmed: 35197626
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
pubmed: 17084815
Brain. 2019 Jun 1;142(6):1503-1527
pubmed: 31039256
Science. 2023 Mar 17;379(6637):1140-1149
pubmed: 36927019
Acta Neuropathol. 2014 Mar;127(3):423-439
pubmed: 24407427
Mol Neurodegener. 2017 Feb 2;12(1):13
pubmed: 28153034
Acta Neuropathol. 2016 Dec;132(6):859-873
pubmed: 27785573
Neurobiol Aging. 2019 May;77:26-36
pubmed: 30776649
Brain. 2019 Nov 1;142(11):3621-3635
pubmed: 31562527
Nature. 2022 Mar;603(7899):131-137
pubmed: 35197628
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3696-705
pubmed: 23188802
Neurobiol Aging. 2012 Mar;33(3):630.e3-8
pubmed: 22118904
Nat Neurosci. 2011 Apr;14(4):459-68
pubmed: 21358643
Acta Neuropathol. 2019 Jan;137(1):27-46
pubmed: 30511086
PLoS One. 2015 Jul 28;10(7):e0134385
pubmed: 26218288
Exp Neurol. 2014 Feb;252:1-11
pubmed: 24246279
Curr Opin Investig Drugs. 2005 Jul;6(7):704-11
pubmed: 16044666
Science. 2015 Aug 7;349(6248):650-5
pubmed: 26250685
Neurobiol Aging. 1996 May-Jun;17(3):331-41
pubmed: 8725893
Lancet Neurol. 2017 Nov;16(11):917-924
pubmed: 28919059
Int J Dev Neurosci. 2013 Feb;31(1):36-45
pubmed: 23070049
Neurobiol Aging. 2013 Aug;34(8):2071-6
pubmed: 23473707
Hum Mol Genet. 2017 Sep 1;26(17):3421-3431
pubmed: 28637276
Am J Alzheimers Dis Other Demen. 2018 May;33(3):153-165
pubmed: 29338302
Front Aging Neurosci. 2021 Jan 22;12:585873
pubmed: 33551786
PLoS One. 2013 Jun 26;8(6):e68324
pubmed: 23840848
J Neuropathol Exp Neurol. 2020 Mar 1;79(3):305-313
pubmed: 31845964
Cell Rep. 2022 Jun 28;39(13):111001
pubmed: 35767949
Acta Neuropathol Commun. 2022 Jul 25;10(1):107
pubmed: 35879741
Acta Neuropathol. 2017 Jun;133(6):923-931
pubmed: 28332094
Nat Neurosci. 2019 Feb;22(2):167-179
pubmed: 30643292
Acta Neuropathol. 2017 Jul;134(1):65-78
pubmed: 28130640
Brain. 2020 Sep 1;143(9):2844-2857
pubmed: 32830216
Brain. 2015 Oct;138(Pt 10):3110-22
pubmed: 26231953
Genomics. 2003 Apr;81(4):400-10
pubmed: 12676564
PLoS Biol. 2023 Mar 17;21(3):e3002028
pubmed: 36930682
Acta Neuropathol. 2009 Feb;117(2):125-36
pubmed: 19139911
J Biol Chem. 2004 Jul 2;279(27):27841-4
pubmed: 15123597
Mol Neurodegener. 2019 Aug 2;14(1):32
pubmed: 31375134
Neuropathology. 2009 Oct;29(5):566-73
pubmed: 19422539
Acta Neuropathol. 2014 Mar;127(3):441-50
pubmed: 24240737
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659
J Neurobiol. 2006 Sep 1;66(10):1101-14
pubmed: 16838365
Acta Neuropathol. 2008 Aug;116(2):215-20
pubmed: 18592255
Nat Genet. 2009 Oct;41(10):1083-7
pubmed: 19734901